Published in Nature on February 20, 1985
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol (1993) 8.62
Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A (1985) 8.53
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 7.27
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58
Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol (1990) 6.54
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol (1988) 5.96
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc Natl Acad Sci U S A (1988) 5.75
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol (1991) 4.82
Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature (1990) 4.81
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol (1999) 4.54
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 4.40
Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol (1991) 4.39
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med (1995) 4.28
Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol (1988) 4.25
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J (1987) 4.14
Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol (1988) 4.13
Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J (1988) 3.98
Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol (1988) 3.88
Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1992) 3.82
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (1992) 3.79
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol (1991) 3.71
Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc Natl Acad Sci U S A (1991) 3.70
Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci U S A (1993) 3.62
Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol (2000) 3.52
Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology (2005) 3.52
Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 3.49
Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A (1987) 3.47
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol (1997) 3.46
A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family. Proc Natl Acad Sci U S A (1994) 3.42
Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med (1992) 3.40
High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A (1985) 3.35
Soluble forms of herpes simplex virus glycoprotein D bind to a limited number of cell surface receptors and inhibit virus entry into cells. J Virol (1990) 3.35
Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol (1993) 3.32
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV. J Virol (1991) 3.28
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol (1990) 3.14
Human immunodeficiency virus can productively infect cultured human glial cells. Proc Natl Acad Sci U S A (1987) 3.14
Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol (1991) 3.09
Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol (1990) 3.07
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog (2012) 3.07
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med (1990) 3.01
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol (1990) 2.96
Reconstructing immune phylogeny: new perspectives. Nat Rev Immunol (2005) 2.95
Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion. J Virol (1990) 2.95
Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol (2002) 2.91
Close is not enough: SNARE-dependent membrane fusion requires an active mechanism that transduces force to membrane anchors. J Cell Biol (2000) 2.91
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol (1990) 2.88
Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2000) 2.86
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol (1998) 2.82
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest (1991) 2.82
Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (2002) 2.81
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol (1992) 2.80
Human immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosis. J Cell Biol (1988) 2.80
Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses. J Virol (1993) 2.77
Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein. J Virol (1991) 2.77
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. Am J Pathol (1986) 2.77
Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med (1997) 2.75
Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol (2003) 2.73
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
Laser capture microdissection. Science (1996) 12.21
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol (1988) 7.37
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem (1982) 6.70
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science (1996) 6.57
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 6.52
Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens. Clin Exp Immunol (1971) 6.43
The cellular basis of immunological responses. A synthesis of some current views. Lancet (1969) 6.05
Infection of human cells by an endogenous retrovirus of pigs. Nat Med (1997) 5.71
Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. Eur J Immunol (1981) 5.32
A new classification for HIV-1. Nature (1998) 5.30
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet (1984) 5.20
Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature (1992) 4.86
High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol (1995) 4.59
Genetic recombinants and heterozygotes derived from endogenous and exogenous avian RNA tumor viruses. Virology (1973) 4.56
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Epitopes of the CD4 antigen and HIV infection. Science (1986) 4.50
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol (1996) 4.43
The CD4 antigen: physiological ligand and HIV receptor. Cell (1988) 4.42
Expression of the CD34 gene in vascular endothelial cells. Blood (1990) 4.41
Ly antigens as markers for functionally distinct subpopulations of thymus-derived lymphocytes of the mouse. Nature (1975) 4.34
HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood (2000) 4.22
Prenatal origin of acute lymphoblastic leukaemia in children. Lancet (1999) 4.21
Receptor interference groups of 20 retroviruses plating on human cells. Virology (1990) 4.15
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1. Immunology (1986) 4.00
Purification of human T and B lymphocytes. J Immunol (1974) 4.00
Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Biol (1984) 4.00
Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J (1988) 3.98
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86
Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 3.84
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Identification of the residues in human CD4 critical for the binding of HIV. Cell (1989) 3.71
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (1997) 3.70
The pH independence of mammalian retrovirus infection. J Gen Virol (1990) 3.68
Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet (1982) 3.67
Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology (1991) 3.54
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
Virus infection of murine teratocarcinoma stem cell lines. Cell (1977) 3.54
Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation. Eur J Immunol (1988) 3.47
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37
Cyclin encoded by KS herpesvirus. Nature (1996) 3.32
Detection of avian tumor virus-specific nucleotide sequences in avian cell DNAs (reassociation kinetics-RNA tumor viruses-gas antigen-Rous sarcoma virus, chick cells). Proc Natl Acad Sci U S A (1972) 3.28
Biological effects of anti-immunoglobulins: evidence for immunoglobulin receptors on 'T' and 'B' lymphocytes. Transplant Rev (1970) 3.23
A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell (1995) 3.17
Blocking of the lymphocyte receptor site for cell mediated hypersensitivity and transplantation reactions by anti-light chain sera. Nature (1969) 3.17
Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol (1975) 3.12
Neutralizing monoclonal antibodies to the AIDS virus. AIDS (1988) 3.06
Separation of suppressor and killer T cells by surgace phenotype. Nature (1976) 3.03
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (1989) 3.01
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med (1990) 3.01
Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. Virology (1971) 3.00
Host range and interference studies of three classes of pig endogenous retrovirus. J Virol (1998) 2.94
Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. Nature (1975) 2.91
HIV infection does not require endocytosis of its receptor, CD4. Cell (1988) 2.88
HIV infection and neoplasia. Lancet (1996) 2.83
Monoclonal antibodies specific for human monocytes, granulocytes and endothelium. Immunology (1984) 2.82
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol (1992) 2.80
Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med (1998) 2.76
Two sets of human-tropic pig retrovirus. Nature (1997) 2.74
Monoclonal antibodies OKT 11 and OKT 11A have pan-T reactivity and block sheep erythrocyte "receptors". Eur J Immunol (1982) 2.72
Cell surface markers for human T and B lymphocytes. Eur J Immunol (1974) 2.70
In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol (1990) 2.70
Expression of an antigen associated with acute lymphoblastic leukemia in human leukemia-lymphoma cell lines. J Natl Cancer Inst (1978) 2.66
T-cell lines producing antigen-specific suppressor factor. Nature (1978) 2.63
Delayed hypersensitivity and lymphocyte transformation in Crohn's disease and proctocolitis. Gut (1969) 2.61
Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol (1992) 2.59
A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science (1997) 2.58
KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene (1997) 2.57
Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia. J Immunol (1979) 2.53
Studies on antigen-binding cells. I. The origin of reactive cells. Cell Immunol (1970) 2.53
Ultrastructural localization of bcl-2 protein. J Histochem Cytochem (1992) 2.48
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (1990) 2.46
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol (1993) 2.46
Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A (1997) 2.45
Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol (1997) 2.42
Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature (1987) 2.40
Activation of T and B lymphocytes by insoluble phytomitogens. Nat New Biol (1972) 2.39
Lymphocyte activation. II. discriminating stimulation of lymphocyte subpopulations by phytomitogens and heterologous antilymphocyte sera. Clin Exp Immunol (1972) 2.37
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36